IIRSM and clinical-stage gene therapy company MeiraGTx today announced an exciting new partnership.

The International Institute of Risk and Safety Management (IIRSM) and clinical-stage gene therapy company MeiraGTx today announced an exciting new partnership.

MeiraGTx is focused on developing potentially curative treatments for patients living with serious diseases, and has six programs in clinical development including four ocular indications, a salivary gland condition, and a Parkinson’s disease program.

With headquarters in New York and London, plus sites in Amsterdam, Shannon and Ghent, MeiraGTx says its global footprint gives it the opportunity to partner with leading institutions around the world, allowing it to deepen its understanding of diseases and their progression.

IIRSM is both a professional membership organisation for those responsible for managing risk in all its forms and a strategic partner of corporates operating across industries.

The Institute works collaboratively for mutual benefit with a wide network of partners and supporters that share its belief that everyone should be empowered to identify, manage and communicate risk.

Together, the two organisations will collaborate on influencing the risk agenda and raising awareness and standards of risk and safety management.

Rosie Russell, Head of EHS & FM at MeiraGTx, said: “MeiraGTx chose to partner with IIRSM to heighten risk awareness and develop risk competencies across key staff. All areas of the business are involved in risk management including EHS, HR, Quality, Legal, Finance, IT, Clinical Operations, R&D, Supply Chain, and many more. 

“IIRSM is the only organisation that welcomes risk practitioners from every discipline and the corporate memberships offer an opportunity for staff to work together across disciplines, develop their skills in risk management and drive professional development, and competence, across the whole organisation.”

IIRSM Chief Executive Phillip Pearson said: “The work of MeiraGTx is vital and revolutionary so we’re thrilled with this collaboration. It gives us the opportunity to support a company that is breaking new ground in finding cures for diseases, and having a positive impact on the lives of people around the world.”

Written by IIRSM

Sign up to our newsletter